Tag Archives: say.

Despite rough start, Biogen’s Aduhelm should find footing, analysts say. But don’t expect much in 2021

As Biogen’s new Alzheimer’s drug Aduhelm makes headlines nearly every day—many covering the drug’s slower-than-expected uptake—one team of biopharma analysts is lowering its 2021 expectations for the med. Nonetheless, despite the drug sputtering out the gate, the team still sees a multibillion-dollar sales opportunity for the company in Alzheimer’s disease. Writing to investors Wednesday, analysts with RBC Capital Markets… Read More »